Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04852523 · ClinicalTrials.gov registry record · Early Phase 1
18F-Fluciclovine PET/CT in the Assessment of Pancreatic Transplants
A Early Phase 1 study of Pancreatitis, Graft and Pancreatic Transplant Post-Transplant Dysfunction Rejection, sponsored by University of Utah.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 4
- Enrollment target
- 1
- Study location
NCT04852523: Completed Early Phase 1 study of Pancreatitis, Graft and Pancreatic Transplant Post-Transplant Dysfunction Rejection, sponsored by University of Utah.
NCT04852523 is a Early Phase 1 study of Pancreatitis, Graft and Pancreatic Transplant Post-Transplant Dysfunction Rejection that has completed, run by University of Utah. The registered enrollment target is 4 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04852523, a Early Phase 1 study of Pancreatitis, Graft and Pancreatic Transplant Post-Transplant Dysfunction Rejection, has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 4 participants
- Enrollment target
- 1
- Study location
Study Summary
Hypothesis 1: 18F-Fluciclovine PET/CT can correctly and easily identify the pancreatic allograft and determine its viability Aim 1: Assess whether 18F-Fluciclovine can identify the pancreatic allograft accurately and assess its viability and visibility Hypothesis 2: 18F-Fluciclovine PET/CT uptake in the pancreas (SUV) is related to total pancreatic function and therefore can indicate whether the pancreatic allograft is at risk of rejection Aim 2: Assess whether 18F-Fluciclovine uptake in the pancreas can be a surrogate for pancreatic function
Primary Outcome
Regions of Interest (ROI) will be placed on the pancreas to determine the standardized uptake value (SUV) which requires the correlation of the patient's standard of care laboratory results. A higher SUV result would indicate stronger viability for the allograft.
Conditions Studied
Interventions
- DRUG 18F-fluciclovine
Study Locations (1)
Utah
- University of Utah Hospital - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2021-09-16 |
| Est. Completion | 2022-10-06 |
| Phase | Early Phase 1 |
What the finished NCT04852523 record still lists
NCT04852523 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (92% lower).
The record links to 2 conditions, with Pancreatitis, Graft appearing as the primary indexed condition, and to 1 intervention - of which 18F-fluciclovine is the first listed.
NCT04852523 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT04852523 about?
NCT04852523 is a clinical study titled "18F-Fluciclovine PET/CT in the Assessment of Pancreatic Transplants". Hypothesis 1: 18F-Fluciclovine PET/CT can correctly and easily identify the pancreatic allograft and determine its viability Aim 1: Assess whether 18F-Fluciclovine can identify the pancreatic allograft accurately and assess its viability and visibility Hypothesis 2: 18F-Fluciclovine PET/CT uptake ...
What is the current status of trial NCT04852523?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 4 participants. The study started on 2021-09-16. Estimated completion is 2022-10-06.
What conditions does trial NCT04852523 study?
This clinical trial studies the following conditions: Pancreatitis, Graft, Pancreatic Transplant Post-Transplant Dysfunction Rejection.
What interventions are being tested in trial NCT04852523?
The interventions under investigation include: 18F-fluciclovine (DRUG).
Who is sponsoring clinical trial NCT04852523?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04852523 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04852523's enrollment target sits among peer trials
4 1922nd of 2000 higher than 53 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI